Skip to main content
. 2021 Jan 1;11(4):1901–1917. doi: 10.7150/thno.51299

Table 1.

KD and KD(FcγRIIIa)/KD(FcγRIIb) ratios of rituximab variants

Rituximab variants KD for FcγRI
(mol/L)
KD for FcγRIIb
(mol/L)
KD for FcγRIIIaF158
(mol/L)
KD for FcγRIIIaV158
(mol/L)
KD for FcγRIIaH131
(mol/L)
KD for FcγRIIaR131
(mol/L)
KD for FcRn
pH 6 (mol/L)
KD for FcRn
pH 7.4 (mol/L)
KD(FcγRIIIaF158)/KD(FcγRIIb) KD(FcγRIIIaV158)/KD(FcγRIIb)
WT 8.67E-09 2.41E-06 9.44E-07 4.03E-07 1.09E-06 1.25E-06 2.10E-08 NB 0.39 0.17
H268E/K326M/I332E 5.15E-09 1.05E-06 1.58E-07 6.91E-08 8.82E-07 7.38E-07 2.60E-08 NB 0.15 0.07
H268E/K326S/I332E 5.18E-09 1.13E-06 1.51E-07 7.47E-08 8.14E-07 8.03E-07 2.50E-08 NB 0.13 0.07
H268E/K326I/I332E 6.11E-09 1.69E-06 3.11E-07 1.43E-07 1.95E-06 1.21E-06 2.57E-08 NB 0.18 0.08
H268E/A330Y/I332D 5.04E-09 1.47E-06 9.40E-08 6.06E-08 5.26E-07 6.8E-07 2.19E-08 NB 0.06 0.04
H268E/A330T/I332E 5.64E-09 9.06E-07 1.56E-07 6.11E-08 6.27E-07 5.75E-07 2.15E-08 NB 0.17 0.07

NB, no measurable binding.